Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Schmieder

Vascular Surgery Louisville, KY Medical Doctor

NPI 1619138005 CMS profile 164238

3999 Dutchmans Ln, Medical Plaza 1, Suite 1H, Louisville, KY 40207

Open in the dashboard

General payments

$44,362

320 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Schmieder of Louisville, KY is reported in the CMS Open Payments database as having received $44,362 across 320 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,579 53
2024 General $10,950 56
2023 General $2,675 35
2022 General $6,778 42
2021 General $4,715 49
2020 General $6,838 35
2019 General $6,828 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Schmieder
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Gregory Schmieder were reported at $5,579. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Gregory Schmieder Vascular Surgery median Middle half National median
2019 $6,828 $796 $226–$2,363 $163
2020 $6,838 $348 $118–$1,110 $114
2021 $4,715 $471 $158–$1,421 $132
2022 $6,778 $725 $222–$2,183 $149
2023 $2,675 $836 $257–$2,440 $160
2024 $10,950 $909 $252–$2,619 $164
2025 $5,579 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $25,871 155 payments
  2. Penumbra, Inc. $3,906 17 payments
  3. Medtronic, Inc. $2,619 31 payments
  4. Inari Medical, Inc. $2,319 17 payments
  5. Silk Road Medical, Inc. $1,693 12 payments
  6. Bolton Medical Inc $874 9 payments
  7. Endologix, Inc. $852 5 payments
  8. Bard Peripheral Vascular, Inc. $828 7 payments
  9. Medtronic Vascular, Inc. $811 14 payments
  10. Shockwave Medical, Inc $477 4 payments
  11. Other $4,113 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $21,389 285 payments
  2. Consulting Fee $14,813 6 payments
  3. Travel and Lodging $8,161 29 payments
Products named General payments · program years 2019–2025
  1. GENERAL - VASCULAR INTERVENTION Vascular $4,806 9 payments
  2. General - Therapies $4,545 7 payments
  3. GENERAL VASCULAR INTERVENTION $3,621 7 payments
  4. Indigo System $3,540 14 payments
  5. CT THROMBECTOMY SYSTEM KIT $2,356 17 payments
  6. FLOWTRIEVER CATHETER, S $2,356 17 payments
  7. ENDURANT IIS $1,474 18 payments
  8. ELUVIA $1,103 27 payments
  9. General - Vascular Intervention General - Vascular Intervention_PI $1,019 4 payments
  10. ENROUTE 0.014 Guidewire $888 6 payments
  11. Other $18,270 221 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

272

Median for Vascular Surgery: 122

Drug cost

$17,322

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 20 $15,812
Clopidogrel Clopidogrel Bisulfate Brand 195 $1,295
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 57 $215

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 108 billing codes

Paid by Medicare

$164,638

Medicare's payments for the services billed

Medicare patients

1,506

Average age 74

Services billed

2,246

742 women, 764 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 48%
Diabetes 43%
Chronic kidney disease 39%
Heart failure 34%
COPD 31%
Atrial fibrillation 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

320 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record